Saturday, November 28, 2020 9:56:21 AM
I got switched to gV. My experience seems to match what many others have posted. I live in Rochester NY and get my scripts filled by Walmart and have Excellus insurance through my wife's company.
Unfortunately I had my wife pick-up my last script and she did not know to check for the switch and brought me home a bottle of Hikma crap. First thing I noticed on the bottle is the label on the top "This is the same medication you have been getting color size or shape may appear different". The Exp. is only Sep 2022. The bottle states it contians 1 gram of Icosapent Ethyl. The label does not have much else on it other than stating "See package insert for complete prescribing information". I have not opened it yet.
(Making a long story short)
I called the Pharmacist and he confirmed that when a manufacture like Hikma labels there product as an exact replacement NY state law requires him to automatically switch me to the generic. Regardless of the indication I am taking it for which is not High Trigs. He admitted he did not know what I was taking it for but no matter his instructions are to replace the prescription with the generic. I asked him the price difference and he stated $20.91 I laughed and stated my coupon then makes Vascepa cheaper to the insurance company than the generic. He admitted he did not know what the insurance company would do about covering it if I switched back to Vascepa. He informed me the only way he can fill the prescription with Vascepa is to have my doctor change the script to say Vascepa instead of Icosapent Ethyl and put DAW(dispense as written). He sent a request to my doctor for the change and I will be calling my doctor on Monday.
I also got a letter in the mail from Excellus stating that Vascepa will be moved to Tier 3 on January 1, 2021 because of generic coming online that will be Tier 1. The letter does state that coverage for Vascepa will continue but a copay increase may start on Januuary 1, 2021. It also states to talk to your doctor if you would consider a lower cost alternative.
I probably cannot return the Hikma crap to the pharmacy but would be glad to send some pills to whomever would like to do there own check out of it. I have not opened the bottle yet but will soon once I verify I cannot return it to the pharmacy. I will be posting as I did before the weight of the capsule the the weight of the contents using my reloading scale good to 1/100 of a gram and of course the smell.
Hope this helps,
Unfortunately I had my wife pick-up my last script and she did not know to check for the switch and brought me home a bottle of Hikma crap. First thing I noticed on the bottle is the label on the top "This is the same medication you have been getting color size or shape may appear different". The Exp. is only Sep 2022. The bottle states it contians 1 gram of Icosapent Ethyl. The label does not have much else on it other than stating "See package insert for complete prescribing information". I have not opened it yet.
(Making a long story short)
I called the Pharmacist and he confirmed that when a manufacture like Hikma labels there product as an exact replacement NY state law requires him to automatically switch me to the generic. Regardless of the indication I am taking it for which is not High Trigs. He admitted he did not know what I was taking it for but no matter his instructions are to replace the prescription with the generic. I asked him the price difference and he stated $20.91 I laughed and stated my coupon then makes Vascepa cheaper to the insurance company than the generic. He admitted he did not know what the insurance company would do about covering it if I switched back to Vascepa. He informed me the only way he can fill the prescription with Vascepa is to have my doctor change the script to say Vascepa instead of Icosapent Ethyl and put DAW(dispense as written). He sent a request to my doctor for the change and I will be calling my doctor on Monday.
I also got a letter in the mail from Excellus stating that Vascepa will be moved to Tier 3 on January 1, 2021 because of generic coming online that will be Tier 1. The letter does state that coverage for Vascepa will continue but a copay increase may start on Januuary 1, 2021. It also states to talk to your doctor if you would consider a lower cost alternative.
I probably cannot return the Hikma crap to the pharmacy but would be glad to send some pills to whomever would like to do there own check out of it. I have not opened the bottle yet but will soon once I verify I cannot return it to the pharmacy. I will be posting as I did before the weight of the capsule the the weight of the contents using my reloading scale good to 1/100 of a gram and of course the smell.
Hope this helps,
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
